MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Nonketotic hyperglycemia-induced hemichorea/hemiballism in El Salvador: A case Series

    R. Lopez-Castellanos, R. Lopez-Contreras (Atlanta, USA)

    Objective: We conducted a retrospective study to investigate the clinical characteristics of patients with nonketotic hyperglycemia-induced hemichorea/hemiballism referred to a movement disorder clinic in El…
  • 2023 International Congress

    Words Spoken Daily: A Novel Measure of Cognition

    S. Lettenberger, M. Zafar, J. Soto, Y. Zhang, G. Zhu, A. Masino, G. Nkrumah, E. Waddell, K. Spear, A. Arky, R. Toor, E. Hartman, J. Epifano, R. Christie, Z. Duan, R. Dorsey (Rochester, USA)

    Objective: To assess the average number of words spoken per day by individuals with Parkinson’s disease (PD), mild cognitive impairment (MCI), and control participants. Background:…
  • 2023 International Congress

    Constipation in Parkinson’s disease, a common problem with rare but serious complications

    S. Lopes, S. Marques, A. Ferreira, S. Varanda, AM. Rodrigues (Braga, Portugal)

    Objective: To report the case of a Parkinson’s disease patient suffering from constipation complicated with a sigmoid volvulus and definitive colostomy Background: Non-motor features of Parkinson's disease…
  • 2023 International Congress

    Comparative Analysis of Stepwise Unilateral and Simultaneous Bilateral Deep Brain Stimulator Electrode Placement for Parkinosn’s Disease

    K. Yekuno, M. Marsans, C. Drolet, J. Roberts, S. Srivastal, F. Farrokhi (Seattle, USA)

    Objective: The goal of this paper is to compare the time required to achieve the maximum possible quality of life (i.e. number of programming visits),…
  • 2023 International Congress

    Differences of social and clinical factors related with distribution of DBS in Mexican PD population

    MF. Medina Pérez, DR. Aguila Godinez, AA. Herrera Ruiz, EC. Santiago Cruz, LG. Lira Juárez, MAG. Medrano Delgado, MA. Ruiz Mafud, AJ. Hernández-Medrano, AY. Regalado Mustafá, DP. Romero-Terán, GI. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Hernandez Armesto, A. Abundes-Corona, AG. Alcocer-Salas (Mexico, Mexico)

    Objective: To identify which social and clinical factors are related to disparities between the distribution of DBS in Mexican PD population Background: Deep Brain stimulation…
  • 2023 International Congress

    Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease

    A. Regalado Mustafá, D. Aguila Godinez, A. Herrera Ruiz, E. Santiago-de-La-Cruz, L. Lira Juárez, M. Medrano Delgado, M. Ruiz Mafud, A. Hernández-Medrano, D. Romero-Terán, M. Medina-Pérez, G. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga, G. Hernandez Armesto, A. Abundes-Corona, A. Domínguez García, J. García Hernández, A. Alcocer Salas, K. Talavera Lagunas (Mexico City, Mexico)

    Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…
  • 2023 International Congress

    Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

    Objective: Objectives: to create and validate an MPTP neurotoxin-based zebrafish model of Parkinson's disease and explore the therapeutic potential and neuroprotective effects of thymoquinone and…
  • 2023 International Congress

    Prevalence of cardiovascular drugs and oral anticoagulants use among persons with and without Parkinson’s disease

    B. Babar (Kuopio, Finland)

    Objective: We investigated prevalence of Cardiovascular drugs and Oral anticoagulants (OAC) use among community-dwelling persons with and without Parkinson's disease (PD) in relation to PD…
  • 2023 International Congress

    Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

    S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

    Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…
  • 2023 International Congress

    Parkinson’s disease (PD) progression is associated with past exposure to organic contaminants in water at Marine Corps Base Camp Lejeune

    S. Goldman, F. Weaver, B. Gonzalez, K. Stroupe, L. Cao, K. Colletta, E. Brown, C. Tanner (San Francisco, USA)

    Objective: To test whether PD progression is more rapid in individuals who were exposed to volatile organic compounds in the water supply at Camp Lejeune…
  • « Previous Page
  • 1
  • …
  • 68
  • 69
  • 70
  • 71
  • 72
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley